Head and neck (HNC) is the tenth most common cancer worldwide with over 650,000 new cases per year [1,2,3]. The major risk factors for development of squamous cell HNC comprise alcohol and tobacco consumption [4]. During the last few decades human papilloma virus (HPV) infection has been identified to contribute to the development of oropharyngeal HNC in a younger subgroup of patients [5]. This population shows a more favorable prognosis compared to HPV-negative disease [5]. Standard treatment options for HNC independent of HPV status include surgery, standard radiation, chemo- or bioradiation and chemotherapy.

Therefore, a multidisciplinary team, involving radiation oncologists, medical oncologists, head and neck surgeons and nutritionists is necessary for the optimal management of these patients throughout the course of their disease. In an effort to improve the outcome both at an early and at an advanced (or even recurrent/metastatic) stage novel treatment concepts have been introduced during the last couple of years.

Minimally invasive surgical techniques such as transoral robotic surgery (TORS) have contributed to reduced morbidity rates, shorter hospital stays and faster recovery times in oropharyngeal cancer patients without endangering the oncological outcomes.

For tumors, however, which are located near the skull base or in a previously irradiated field, particle therapy employing protons can provide a novel treatment option accompanied with reduced side effects compared to conventional photon therapy. In addition to protons, carbon ions recently entered the stage providing benefits for the treatment of radioresistant histologies such as adenoid cystic carcinomas.

Despite the improvements outlined above, recurrence rates of stage III/IV disease after curative therapy is about 50% in the first 2 years of follow-up [6, 7]. For patients, who are not amenable to salvage surgery, only limited palliative treatment options such as systemic chemotherapy and targeted treatments exist resulting in a median overall survival of 10 months [8].

With the advent of immuno-oncology and the approval of immune checkpoint inhibitors, which target the interaction between PD‑1 and PDL‑1, the prognosis of HNC patients in the recurrent/metastatic setting has improved substantially.

However, we must not forget that HNC is a heterogeneous disease: While 90% of HNC are squamous cell carcinomas, salivary gland carcinomas (SGC) account for approximately 6–8% of HNC. Since the evidence from clinical trials is sparse, metastatic SGC pose a therapeutic challenge. The increasing availability of next generation sequencing (NGS) and intensive research efforts shed light onto the molecular alterations of SGC, which can be exploited utilizing targeted therapies such as trastuzumab in HER2-positive SGC or hormone-based treatment options in androgen-receptor positive cases.

Finally, the relevance of nutritional counseling has to be emphasized: Since HNC patients are frequently malnourished, early intervention is essential in order to improve not only quality of life, but also oncological outcome.

We want to thank the experts who contributed to this series and provided an update about the current developments for the treatment of HNC from the surgeon’s, radiation oncologist’s, medical oncologist’s and nutritionist’s point of view [9,10,11,12,13].